RYTM has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
RYTM has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Liabilities-to-Assets is a solvency ratio indicating how much of the company’s assets are made of liabilities, calculated as total liabilities divided by total asset. Rhythm Pharmaceuticals's Total Liabilities for the quarter that ended in Dec. 2024 was $227.7 Mil. Rhythm Pharmaceuticals's Total Assets for the quarter that ended in Dec. 2024 was $392.3 Mil. Therefore, Rhythm Pharmaceuticals's Liabilities-to-Assets Ratio for the quarter that ended in Dec. 2024 was 0.58.
The historical data trend for Rhythm Pharmaceuticals's Liabilities-to-Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Rhythm Pharmaceuticals Annual Data | |||||||||||||||||||||
Trend | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | Dec24 | |||||||||||
Liabilities-to-Assets | Get a 7-Day Free Trial |
![]() |
![]() |
0.11 | 0.14 | 0.31 | 0.49 | 0.58 |
Rhythm Pharmaceuticals Quarterly Data | ||||||||||||||||||||
Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | Dec24 | |
Liabilities-to-Assets | Get a 7-Day Free Trial |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
0.49 | 0.76 | 0.53 | 0.58 | 0.58 |
For the Biotechnology subindustry, Rhythm Pharmaceuticals's Liabilities-to-Assets, along with its competitors' market caps and Liabilities-to-Assets data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Rhythm Pharmaceuticals's Liabilities-to-Assets distribution charts can be found below:
* The bar in red indicates where Rhythm Pharmaceuticals's Liabilities-to-Assets falls into.
Liabilities-to-Assets ratio measures the portion of the total liabilities to the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Liabilities-to-Assets ratio is calculated by dividing total liabilities by total asset.
Rhythm Pharmaceuticals's Liabilities-to-Assets Ratio for the fiscal year that ended in Dec. 2024 is calculated as:
Liabilities-to-Assets (A: Dec. 2024 ) | = | Total Liabilities | / | Total Assets |
= | 227.724 | / | 392.273 | |
= | 0.58 |
Rhythm Pharmaceuticals's Liabilities-to-Assets Ratio for the quarter that ended in Dec. 2024 is calculated as
Liabilities-to-Assets (Q: Dec. 2024 ) | = | Total Liabilities | / | Total Assets |
= | 227.724 | / | 392.273 | |
= | 0.58 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Rhythm Pharmaceuticals (NAS:RYTM) Liabilities-to-Assets Explanation
Liabilities-to-Assets is a solvency ratio indicating how much of the company’s assets are made of liabilities. It can vary greatly across different industries, as they have different capital structure. A high Liabilities-to-Assets ratio (more leveraged) suggests that the company might have potential solvency problems, or even a signal of financial distress. Conversely, a low Liabilities-to-Assets ratio usually indicates a healthy financial situation. However, it may also suggest that the company is not expanding or not making good use of debt.
Thank you for viewing the detailed overview of Rhythm Pharmaceuticals's Liabilities-to-Assets provided by GuruFocus.com. Please click on the following links to see related term pages.
Yann Mazabraud | officer: EVP, Head of International | C/O TREVI THERAPEUTICS, INC., 195 CHURCH STREET, FLOOR 14, NEW HAVEN CT 06510 |
Christopher Paul German | officer: Corporate Controller & CAO | C/O RHYTHM PHARMACEUTICALS, 222 BERKELEY STREET, SUITE 1200, BOSTON MA 02116 |
Pamela J. Cramer | officer: Chief Human Resources Officer | C/O RHYTHM PHARMACEUTICALS, 222 BERKELEY STREET, SUITE 1200, BOSTON MA 02116 |
Joseph Shulman | officer: Chief Technical Officer | C/O RHYTHM PHARMACEUTICALS, 222 BERKELEY STREET, SUITE 1200, BOSTON MA 02116 |
Hunter C Smith | officer: CFO and Treasurer | C/O GENESEE & WYOMING INC., 20 WEST AVENUE, DARIEN CT 06820 |
Jennifer Chien | officer: EVP, Head of North America | C/O KRYSTAL BIOTECH, INC., 2100 WHARTON STREET, SUITE 701, PITTSBURGH PA 15203 |
David P Meeker | director | C/O PENWEST PHARMACEUTICALS CO, 39 OLD RIDGEBURY ROAD SUITE 11, DANBURY CT 06810 |
Jennifer L Good | director | 15 GREAT RING ROAD, SANDY HOOK CT 06482 |
Lynn A. Tetrault | director | 12701 COMMONWEALTH DRIVE, SUITE 9, FORT MYERS FL 33913 |
William T. Roberts | officer: Chief Accounting Officer | C/O RHYTHM PHARMACEUTICALS, 222 BERKELEY STREET, SUITE 1200, BOSTON MA 02116 |
Linda Shapiro Manning | officer: Chief Medical Officer | C/O RHYTHM PHARMACEUTICALS, 222 BERKELEY STREET, SUITE 1200, BOSTON MA 02116 |
Todd Foley | director, 10 percent owner | THE JOHN HANCOCK TOWER, 200 CLARENDON STREET 54TH FLOOR, BOSTON MA 02116 |
Camille L Bedrosian | director | C/O ULTRAGENYX PHARMACEUTICAL INC., 60 LEVERONI COURT, NOVATO CA 94949 |
Ra Capital Healthcare Fund Lp | 10 percent owner | 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116 |
Nithya Desikan | officer: Chief Commercial Officer | 82 BAY STATE ROAD, BELMONT MA 02478 |
From GuruFocus
By GuruFocus News • 02-26-2025
By Marketwired • 11-13-2024
By GuruFocus News • 02-08-2025
By GuruFocus News • 02-11-2025
By Marketwired • 01-10-2025
By Marketwired • 03-19-2025
By Marketwired • 02-13-2025
By Marketwired • 11-18-2024
By GuruFocus News • 11-07-2024
By GuruFocus News • 11-13-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.